{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:44:30Z","timestamp":1769208270788,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,10,15]],"date-time":"2007-10-15T00:00:00Z","timestamp":1192406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To describe long term outcomes of <jats:italic>Mycobacterium avium<\/jats:italic> complex (MAC) immune reconstitution inflammatory syndrome (IRIS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Cases of MAC IRIS were retrospectively identified at four HIV clinics (Michigan, Maryland, Rhode Island, and Indiana) from 1996\u20132004. Patients were included if they were initially diagnosed with AIDS and found to have evidence of focal MAC infection documented by tissue culture or PCR after initiating HAART, and at least 6 months of follow up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 20 patients included, the mean age was 40 years, mean CD4 cell count was 24\/mm<jats:sup>3<\/jats:sup> at pretreatment baseline and 100\/mm<jats:sup>3<\/jats:sup> at time of MAC IRIS diagnosis. Sites of disease included lymph nodes (15 patients [8 peripheral, 8 abdominal and 1 peripheral and abdominal]), gastrointestinal tract (7) and liver (3). Sixteen patients (80%) responded to treatment and were disease free after a mean of 17.4 months of therapy for MAC IRIS; IRIS therapy was withdrawn in 6 without relapse. Four patients (non-responder group) had persistent or relapsing disease despite 27 months of ongoing MAC IRIS treatment. At the time of resolution or last follow-up, the mean CD4 cell count and viral load was 143\/mm<jats:sup>3<\/jats:sup> and 7,000 c\/mL for responders, and 65\/mm<jats:sup>3<\/jats:sup> and 17,000 c\/mL for non-responders, respectively. Most patients with peripheral adenopathy were responders (7\/8; 88%); many with abdominal adenopathy (4\/8; 50%) were nonresponders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The majority of patients with MAC IRIS eventually responded to treatment. Our sample size was not adequate to perform statistical analysis, but there was a tendency towards adequate CD4 response to HAART and peripheral rather than intraabdominal adenopathy among responders.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1479-5876-5-50","type":"journal-article","created":{"date-parts":[[2007,10,16]],"date-time":"2007-10-16T06:14:15Z","timestamp":1192515255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes"],"prefix":"10.1186","volume":"5","author":[{"suffix":"IV","given":"James","family":"Riddell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros C","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel E","family":"Gallant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Mitty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Powel H","family":"Kazanjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,15]]},"reference":[{"key":"210_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0140-6736(97)04352-3","volume":"351","author":"EM Race","year":"1998","unstructured":"Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ: Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 1998, 351: 252-255. 10.1016\/S0140-6736(97)04352-3.","journal-title":"Lancet"},{"issue":"2","key":"210_CR2","first-page":"122","volume":"20","author":"P Phillips","year":"1999","unstructured":"Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J: Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. JAIDS. 1999, 20 (2): 122-128.","journal-title":"JAIDS"},{"issue":"3","key":"210_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/00005792-200205000-00005","volume":"81","author":"SA Shelburne","year":"2002","unstructured":"Shelburne SA, Hamill RJ, Rodriquez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trauntner BW: Immune reconstitution inflammatory syndrome: Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine. 2002, 81 (3): 213-227. 10.1097\/00005792-200205000-00005.","journal-title":"Medicine"},{"key":"210_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1473-3099(05)70140-7","volume":"5","author":"SD Lawn","year":"2005","unstructured":"Lawn SD, Bekker LG, Miller RF: Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005, 5: 361-373. 10.1016\/S1473-3099(05)70140-7.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"210_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1089\/108729103771928672","volume":"17","author":"JA Desimone","year":"2003","unstructured":"Desimone JA, Babinchak TJ, Kaulback KR, Pomerantz RJ: Treatment of mycobacterium avium complex immune reconstitution disease in HIV-1 infected individuals. AIDS Patient Care STDS. 2003, 17 (12): 617-622. 10.1089\/108729103771928672.","journal-title":"AIDS Patient Care STDS"},{"issue":"10","key":"210_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1258\/0956462001914940","volume":"11","author":"L Price","year":"2000","unstructured":"Price L, O'Mahony C: Focal adenitis developing after immune reconstitution with HAART. Int J STD AIDS. 2000, 11 (10): 685-686. 10.1258\/0956462001914940.","journal-title":"Int J STD AIDS"},{"issue":"11","key":"210_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/108729103322555935","volume":"17","author":"CO Cunningham","year":"2003","unstructured":"Cunningham CO, Selwyn PA: Mastitis due to mycobacterium avium complex in an HIV-infected woman taking highly active antiretroviral therapy. AIDS Patient Care STDS. 2003, 17 (11): 547-550. 10.1089\/108729103322555935.","journal-title":"AIDS Patient Care STDS"},{"issue":"9108","key":"210_CR8","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S0140-6736(98)26014-4","volume":"351","author":"G DiPerri","year":"1998","unstructured":"DiPerri G, Bonora S, Vento S, Allegranzi B, Concia E: Highly active antiretroviral therapy. Lancet. 1998, 351 (9108): 1056-1066. 10.1016\/S0140-6736(98)26014-4.","journal-title":"Lancet"},{"issue":"3","key":"210_CR9","first-page":"24","volume":"15","author":"ER Jenny-Avital","year":"2003","unstructured":"Jenny-Avital ER: A patient with refractory disseminated Mycobacterium avium after immune-reconstitution localized MAC. AIDS Clin Care. 2003, 15 (3): 24-26.","journal-title":"AIDS Clin Care"},{"issue":"3","key":"210_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1086\/313705","volume":"30","author":"SK Cinti","year":"2000","unstructured":"Cinti SK, Kaul DR, Sax PE, Crane LR, Kazanjian PH: Recurrence of mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis. 2000, 30 (3): 511-514. 10.1086\/313705.","journal-title":"Clin Infect Dis"},{"key":"210_CR11","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1086\/497269","volume":"41","author":"P Phillips","year":"2005","unstructured":"Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, O'Shaughnessy M, Montaner J: Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: Spectrum of disease and long-term follow-up. Clin Infect Dis. 2005, 41: 1483-1497. 10.1086\/497269.","journal-title":"Clin Infect Dis"},{"key":"210_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/01.aids.0000161769.06158.8a","volume":"19","author":"SA Shelburne","year":"2005","unstructured":"Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ: Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005, 19: 399-406. 10.1097\/01.aids.0000161769.06158.8a.","journal-title":"AIDS"},{"key":"210_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1086\/503903","volume":"42","author":"J Robertson","year":"2006","unstructured":"Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ: Immune reconstitution syndrome in HIV: Validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006, 42: 1639-1646. 10.1086\/503903.","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-5-50.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1479-5876-5-50\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-5-50.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:49:42Z","timestamp":1630453782000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-5-50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,15]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["210"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-5-50","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,15]]},"assertion":[{"value":"10 July 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"50"}}